Morphic Medical today announced the addition of James Reinstein, Teresa Matterelli, and John Barr to the company’s Board of Directors

GI Dynamics is proud to announce its rebrand to Morphic Medical and the introduction of RESET, formally known as EndoBarrier®.

Data demonstrate favorable safety and efficacy profile for the duodenal jejunal bypass liner (DJBL) technology.

Trial to focus on reduction of hemoglobin A1c for patients diagnosed with type 2 diabetes and obesity.

Studies demonstrate the safety and efficacy profile that EndoBarrier provides patients diagnosed with type 2 diabetes and/or obesity.

Initial results show the duodenal jejunal bypass liner (DJBL) technology met overall glycemic control efficacy and SAE related device removal safety endpoints. Findings Presented at DDW 2022 BOSTON.

Trial to focus on reduction of hemoglobin A1c for patients diagnosed with type 2 diabetes and obesity.

Joseph Virgilio appointed as president and chief executive officer of GI Dynamics, Mark Lerdal as chairman of the Board of Directors, and Ginger Glaser as non-executive director to the Board.

Initial closing of its private placement offering of Series A Preferred Stock led by Crystal Amber Fund Limited (“Crystal Amber”), the Company’s majority stockholder.

Update regarding the removal of the Company from the Official List of the Australian Securities Exchange (“ASX”).

Crystal Amber has provided a notice to convert all of the outstanding principal and accrued interest owed under the June 2017 Note.

Update regarding the extension of the maturity date of the Senior Secured Convertible Promissory Note issued to Crystal Amber Fund Limited (“Crystal Amber”).

Resolution approved to delist Company from the Official List of the Australian Securities Exchange (“ASX”) (“Official List”).

GI Dynamics announced that it has issued a US$750,000 Unsecured Convertible Promissory Note to Crystal Amber Fund Limited (“Crystal Amber”), the Company’s largest stockholder.

Update regarding the extension of the maturity date of the Senior Secured Convertible Promissory Note issued to Crystal Amber Fund Limited (“Crystal Amber”) on 15 June 2017 and associated matters.

Further postponement of Special Meeting of Stockholders that was due to be held on 16 June 2020 at 6:00 pm US Eastern Daylight Time, which is 17 June 2020 at 8:00 am Australian Eastern Standard Time.

Postponement of Special Meeting of Stockholders originally scheduled to be held on 7 June 2020 at 6:00 pm US Eastern Daylight Time, which is 8 June 2020 at 8:00 am Australian Eastern Standard Time.

Company has applied to the Australian Securities Exchange (ASX) for its formal approval for delisting of the Company from the Official List of the ASX and update in relation to this and associated matters.

Extension of maturity date of June 2017 note and further financing update.

Timothy Barberich resigned as a non-executive director of its Board of Directors effective as of 30 March 2020. Mr. Barberich joined the Board in 2011.

Increase in the size of the Board from four to five directors and elected Dr. Praveen Tyle, Ph.D. to fill such vacancy and serve as a Class III director to serve until the 2020 Annual Meeting of Stockholders.

First patient in the United States STEP-1 clinical trial has been enrolled at Michigan Medicine in Ann Arbor, Michigan.

Positive EndoBarrier data from the University of Freiburg in Germany showing improvements of cardiovascular risk (CV) biomarkers and predicted 4-year risk of major CV events.

GI Dynamics has received the relevant funding amount under the convertible note issued to Crystal Amber Fund Limited (Crystal Amber), on 22 August 2019 (2019 Note), being an amount of US$4,596,893.